IMNN logo

IMUNON INC

IMNNNASDAQ
🏆 #5145 by market capEarnings Nov 11US Equity
$526.47▼ $29.85 (−5.67%)
Simulated price
🔔
Track IMNN
Get earnings, price moves & breaking news on Telegram
Track
24h▼ 5.7%
7d—
14d—
30d—
ytd—
1y—
🏦Market Cap
$6M
Small Cap
📈Revenue Growth (YoY)
+0.0%
Slowing
📊Gross Margin
0.0%
Thin
💵FCF Margin
0.0%
Thin
⚖️P/S Ratio
0.0x
Cheap
Otter Score
44
Weak
No chart data available for IMNN.

Trading Snapshot

Day Range
$520.73 – $536.34
52-Week Range
$1.30 – $5.55
Volume
$2.49B
Avg Volume
$2.72B
Shares Outstanding
4.2M
Next Earnings
Nov 18, 2026

Fundamentals Snapshot

Annual Revenue
$487,304
Last Q Revenue
$121,704
P/E Ratio
-0.3
P/S Ratio
0.0x
EPS (TTM)
$-2.81
Dividend Yield
0.00%
Dilution (1yr)
+91.0%

Why Investors Own IMNN

  • ✓High-growth profile — revenue up +25.4% YoY with expanding US Equity exposure.
  • ✓Healthy economics — 39% gross margin and 28% free-cash-flow margin.
  • ✓New products and segments could unlock additional revenue streams.
⚠️ Key Risks

Execution delays, intensifying competition, and valuation compression if growth decelerates.

IMNN logo

IMUNON INC

IMNN
Financial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$0▲ +0.0% YoY
Gross MarginOf every $1 of sales, how much is left after the direct cost of making the product/service. Higher = more efficient.
100.0%▲ +0.0% YoY
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
−$15M▼ −23.4% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
−$14M▼ −24.9% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
2.1M▲ +91.0% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
$8M▲ +$3M YoY
StockOtter · stockotter.space

About IMUNON INC

Imunon, Inc. is a clinical-stage biotechnology company dedicated to the development and commercialization of DNA-based immunotherapies, vaccines, and directed chemotherapies. The company's pipeline features GEN-1, a DNA-based immunotherapy specifically designed for the localized treatment of ovarian cancer, and ThermoDox, a proprietary heat-activated liposomal formulation of doxorubicin, currently in development for various cancer indications. Additionally, Imunon possesses two feasibility-stage platform technologies aimed at creating nucleic acid-based immunotherapies, vaccines, and other anti-cancer DNA or RNA therapies. Established in 1982 and based in Lawrenceville, New Jersey, the firm was known as Celsion Corporation before rebranding to Imunon, Inc. in September 2022.

🦦

Otter Score Breakdown

How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)
💎Quality★★★★★
🚀Growth★★★★★
⚖️Valuation★★★★★
⚡Momentum★★★★★
💧Dilution★★★★★
Overall Score
Weak
44/100

Analyst Price Target

ⓘ
Average Target
$524.66
▼ −0.3% Downside
High Target$589.94
Low Target$489.90
Based on 21 analysts

Latest News & Updates

🚀
Barron’s·2h ago

IMUNON INC tops quarterly estimates as demand accelerates

Revenue grew double digits with management guiding above consensus; margins continued to expand.

🛰️
Reuters·5h ago

Analysts lift IMNN price targets on improving margins

Several firms raised targets, citing stronger free cash flow and a healthier backlog.

🌌
Reuters·1d ago

IMUNON INC announces new agreement to expand its footprint

The move broadens the company’s reach and could add incremental revenue over the next year.